59.3 Chronic Myopathies & Fibromyalgia Syndrome

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

59.3 Chronic Myopathies & Fibromyalgia Syndrome

Key Takeaways Explain This Topic AI

Fibromyalgia syndrome (FMS) is a prototype centralized pain amplification disorder (nociplastic pain) characterized by central sensitization, impaired descending inhibitory noradrenergic/serotonergic pathways, and elevated CSF substance P and glutamate levels, presenting with chronic widespread musculoskeletal pain, profound fatigue, and unrefreshing sleep.

The 2016 revised ACR diagnostic criteria eliminate the historic 1990 requirement for 11/18 tender points, establishing diagnosis based on Widespread Pain Index (WPI >=7) with Symptom Severity Scale (SSS >=5) or WPI 4-6 with SSS >=9, pain in >=4 of 5 body regions, symptom persistence for >=3 months, and confirmation that FMS is not a diagnosis of exclusion (can co-exist with other somatic and rheumatologic diseases).

Diagnostic laboratory evaluation in suspected fibromyalgia should be strictly targeted to exclude common organic mimics (CBC, ESR, CRP, TSH, CK, calcium, vitamin D); routine extensive autoantibody testing (ANA, RF) in the absence of objective synovitis or autoimmune features is contraindicated due to high false-positive rates.

Non-pharmacologic therapy (graded low-impact aerobic exercise, cognitive behavioral therapy, sleep hygiene) forms the cornerstone of effective management; FDA-approved pharmacotherapies include duloxetine, milnacipran, and pregabalin, while opioids and systemic corticosteroids are strictly contraindicated due to lack of efficacy and risk of opioid-induced hyperalgesia.

Evaluation of chronic myopathies requires distinguishing muscular weakness from centralized pain: statin-induced myopathy (elevated CK resolving upon discontinuation; anti-HMGCR in necrotizing autoimmune forms), hypothyroid myopathy (elevated CK, elevated TSH, pseudomyotonia), glucocorticoid-induced myopathy (painless proximal muscle weakness with completely normal CK and normal inflammatory markers), and inclusion body myositis (older males, asymmetric weakness of deep finger flexors and quadriceps, biopsy showing rimmed vacuoles).

Last updated: September 2026

Fibromyalgia Syndrome: Neurobiology & Centralized Pain Amplification

Fibromyalgia Syndrome (FMS) is a common chronic pain disorder affecting 2% to 4% of the global population, characterized by widespread musculoskeletal aching, unrefreshing sleep, debilitating fatigue, and cognitive dysfunction. In 2017, the International Association for the Study of Pain (IASP) formally recognized a third mechanistic descriptor for chronic pain: Nociplastic Pain —defined as pain that arises from altered nociceptive processing despite no clear evidence of actual or threatened tissue damage activating peripheral nociceptors, nor evidence of primary lesion or disease of the somatosensory nervous system. Fibromyalgia serves as the prototypical nociplastic centralized pain disorder.

Neurobiological Mechanisms of Central Sensitization

Rigorous neuroimaging, neurochemical, and quantitative sensory testing (QST) studies have demonstrated that fibromyalgia is not a psychological or peripheral muscle/joint disease, but a neurobiological disorder of centralized pain regulation ("the central volume control setting is turned up high"):

Augmented Ascending Nociceptive Facilitation : Cerebrospinal fluid (CSF) analysis in patients with fibromyalgia reveals a 2- to 3-fold elevation in Substance P , as well as significantly elevated concentrations of Glutamate and Nerve Growth Factor (NGF). Excessive synaptic glutamate binds postsynaptic N-methyl-D-aspartate (NMDA) receptors in the dorsal horn of the spinal cord, precipitating temporal summation (the "wind-up" phenomenon) , whereby repetitive, low-intensity peripheral sensory inputs produce progressive, escalating amplification of pain signals.

Deficient Descending Inhibitory Pain Pathways : In healthy individuals, descending bulbospinal tracts originating in the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) release serotonin and norepinephrine into the dorsal horn, suppressing incoming pain traffic (diffuse noxious inhibitory control / Conditioned Pain Modulation [CPM]). In fibromyalgia, CSF levels of serotonin, norepinephrine, and dopamine metabolites are markedly reduced, indicating a profound failure of endogenous descending analgesic gating.

Functional Neuroimaging Alterations : Functional Magnetic Resonance Imaging (fMRI) reveals exaggerated Blood-Oxygen-Level-Dependent (BOLD) activation of the cerebral "pain matrix" (somatosensory cortices S1 and S2, anterior cingulate cortex [ACC], and insular cortex) in response to light tactile pressure that healthy controls perceive as painless ( Allodynia ) and exaggerated pain responses to mildly painful stimuli ( Hyperalgesia ). Furthermore, resting-state fMRI demonstrates hyperconnectivity between the default mode network (DMN) and the pro-nociceptive insular cortex.

Sleep Architecture & Neuroendocrine Derangement : Polysomnography characteristically demonstrates alpha-delta sleep : the continuous abnormal intrusion of rapid alpha waves (7-12 Hz, typical of wakefulness) into deep, slow-wave delta sleep (stage 3 and 4 non-REM sleep). This disrupted architecture prevents restorative physiological sleep, suppresses nocturnal human growth hormone release, and impairs muscle tissue repair. Patients also exhibit blunting of the hypothalamic-pituitary-adrenal (HPA) axis with an abnormal, flattened diurnal cortisol curve.

Clinical Presentation & The Symptom Complex THE TETRAD OF CORE FIBROMYALGIA MANIFESTATIONS

• Clinical Domain Phenotypic Features Pathophysiological Correlate
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Widespread Pain Aching, burning, gnawing, stiffness affecting muscles, Central sensitization; lower pain thresholds

• joints, and soft tissues bilaterally, above and across all dermatomal / myotomal levels
• below the waist, and throughout the axial skeleton
• ─────────────────────────────────────────────────────────────────────────────────────────────────────────

Debilitating Fatigue Severe physical exhaustion unalleviated by rest; HPA axis blunting, neuroendocrine dysregulation,

• most severe upon waking; exercise intolerance depleted central monoamines
• ─────────────────────────────────────────────────────────────────────────────────────────────────────────

Non-Restorative Sleep Waking feeling completely unrefreshed ("like I never Alpha-wave intrusion into delta slow-wave sleep;

• slept" or "run over by a truck"); frequent awakenings absence of restorative stage 3/4 non-REM sleep
• ─────────────────────────────────────────────────────────────────────────────────────────────────────────

Cognitive Dysfunction Slowed processing speed, impaired working memory, Altered insular-DMN connectivity; interference

• ('Fibro Fog') poor concentration, word-finding difficulty from continuous nociceptive processing
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Overlapping Somatosensory Syndromes

Fibromyalgia rarely occurs in isolation; it characteristically clusters with other functional centralized somatic conditions:

Irritable Bowel Syndrome (IBS) (present in 50% to 70% of patients): Recurrent abdominal pain, bloating, and altered bowel habits (diarrhea/constipation) driven by visceral hyperalgesia.

Temporomandibular Disorder (TMD) : Bilateral facial pain, jaw clicking, and masticatory muscle tenderness.

Chronic Headaches : Severe tension-type headaches and migraines (present in >50%).

Interstitial Cystitis / Bladder Pain Syndrome : Pelvic pain, urinary frequency, urgency, and suprapubic discomfort with sterile urine cultures.

Subjective Neurological Dysesthesias : Numbness, tingling, or "electric crawling" sensations in the hands and feet without objective dermatomal sensory deficits or motor weakness.

• Evolution of Diagnostic Criteria: 1990 vs. 2016 Revised ACR Criteria
• Historical Context: The Flawed 1990 Tender Point Examination

The initial 1990 American College of Rheumatology (ACR) criteria required: 1) A history of chronic widespread pain for >=3 months, AND 2) Pain on digital palpation (with approximately 4 kg/cm² of force, enough to blanch the examiner's thumbnail) at at least 11 of 18 specific tender point sites . The 1990 criteria were severely flawed:

Primary care clinicians rarely performed the tender point exam correctly or consistently;

Male patients were heavily underdiagnosed because men naturally have higher mechanical pressure thresholds, falsely cementing a perceived 9:1 female predominance;

Most critically, the 1990 criteria completely ignored the defining non-pain symptoms: sleep disruption, profound fatigue, and cognitive dysfunction.

The 2016 Revised ACR Diagnostic Criteria

The ACR revised criteria completely eliminated the manual tender point examination , replacing it with a validated, quantitative clinical scoring system based on two validated scales: 2016 REVISED ACR DIAGNOSTIC CRITERIA SCORING

• Diagnostic Metric Definition & Scoring Mechanism
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Widespread Pain Index (WPI) Counts the number of painful anatomical areas over the PAST 7 DAYS (Score: 0 - 19):

• Left Shoulder girdle • Right Shoulder girdle • Left Hip / Buttock
• Left Upper arm • Right Upper arm • Right Hip / Buttock
• Left Lower arm • Right Lower arm • Left Upper leg
• Left Lower leg • Right Lower leg • Right Upper leg
• Left Jaw • Right Jaw • Right Lower leg
• Chest • Abdomen • Neck
• Upper back • Lower back
• ─────────────────────────────────────────────────────────────────────────────────────────────────────────

Symptom Severity Scale (SSS) Part 2a: Core Symptoms (Score 0=none, 1=mild, 2=moderate, 3=severe over past week):

• 1. Fatigue (0 - 3)
• 2. Waking unrefreshed (0 - 3)
• 3. Cognitive symptoms / "fibro fog" (0 - 3)

Part 2b: Somatic Symptoms (Score 0 to 3 total):

• Presence during previous 6 months of: Headaches (0/1), Pain/cramps in
• lower abdomen (0/1), and Depression (0/1). (Total SSS Score: 0 - 12)
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• The Formal Diagnostic Rule (2016 Update)

A patient meets formal diagnostic criteria for Fibromyalgia if ALL FOUR of the following conditions are satisfied:

Score Cutoff : WPI >= 7 AND SSS >= 5 , OR WPI 4 to 6 AND SSS >= 9 ;

Generalized Pain Distribution : Pain is present in at least 4 of 5 anatomical regions :

• Region 1 (Left Upper): Left shoulder, left upper arm, left lower arm
• Region 2 (Right Upper): Right shoulder, right upper arm, right lower arm
• Region 3 (Left Lower): Left hip/buttock, left upper leg, left lower leg
• Region 4 (Right Lower): Right hip/buttock, right upper leg, right lower leg
• Region 5 (Axial): Neck, upper back, lower back, chest, or abdomen
• Duration : Symptoms have been present at a similar, consistent level for at least 3 months ;

Validity with Other Illnesses : A diagnosis of fibromyalgia is valid irrespective of other diagnoses . Fibromyalgia is NO LONGER a diagnosis of exclusion . A patient can have both active Rheumatoid Arthritis or Systemic Lupus Erythematosus and concomitant Fibromyalgia (secondary/concomitant fibromyalgia occurs in 15% to 30% of patients with inflammatory rheumatologic disease).

Prudent Diagnostic Workup & Avoiding Over-Investigation

Because fibromyalgia produces diffuse aching, patients frequently undergo exhaustive, expensive, and unnecessary medical testing. The primary care physician must execute a targeted, rational initial laboratory evaluation aimed strictly at ruling out common organic mimics, while aggressively avoiding extensive autoimmune panels.

The Targeted Baseline Laboratory Panel

Complete Blood Count (CBC) : Rules out occult anemia, hematologic malignancies, and cytopenias.

Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP) : CRITICAL EXAM PEARL: ESR and CRP are strictly NORMAL in primary fibromyalgia . An elevated ESR or CRP is a major red flag indicating an occult systemic inflammatory disease (e.g., Polymyalgia Rheumatica, Rheumatoid Arthritis, systemic vasculitis, occult infection, or malignancy) and points away from isolated fibromyalgia.

Thyroid-Stimulating Hormone (TSH) : Rules out hypothyroidism, which mimics fibromyalgia with fatigue, diffuse myalgias, weight gain, constipation, and cognitive slowing.

Serum Creatine Kinase (CK) : Strictly NORMAL in fibromyalgia . An elevated CK indicates a true myopathy (inflammatory myositis, statin-induced myopathy, muscular dystrophy, or hypothyroid myopathy).

Serum Calcium and 25-OH Vitamin D : Evaluates for hyperparathyroidism, hypocalcemia, and severe osteomalacia.

Caution

THE HAZARD OF ORDERING ROUTINE ANA AND RHEUMATOID FACTOR Antinuclear Antibodies (ANA) and Rheumatoid Factor (RF) should NEVER be ordered routinely in patients presenting with chronic widespread pain in the absence of objective physical signs of connective tissue disease (e.g., true inflammatory joint synovitis/effusion, malar rash, discoid lesions, oral ulcers, photosensitivity, Raynaud phenomenon, sclerodactyly, or alopecia).

In the general population, up to 20% to 30% of healthy women have a low-positive ANA titer (1:40 to 1:80) . Ordering an ANA in a low-prevalence setting produces a devastatingly high false-positive rate, precipitating severe patient anxiety, inappropriate rheumatology referrals, and dangerous misdiagnoses that subject patients to toxic, unnecessary immunosuppressive therapies.

Comprehensive Management of Fibromyalgia

Successful management of fibromyalgia requires a patient-centered, multimodal approach that integrates non-pharmacologic therapies as the primary foundation, supplemented by targeted, evidence-based pharmacotherapies. EVIDENCE-BASED MANAGEMENT OF FIBROMYALGIA SYNDROME

• Treatment Modality Specific Therapeutic Agent Clinical Directive & Mechanism of Action
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• FOUNDATIONAL CORE • Graded Aerobic Exercise MOST EFFECTIVE PROVEN INTERVENTION (walking, aquatic
• (Non-Pharmacologic) therapy, cycling); "start low and go slow"
• Cognitive Behavioral Therapy (CBT) Reduces pain catastrophizing, enhances coping mechanisms
• Sleep Hygiene Education Fixed sleep schedule, blue-light reduction, no midday caffeine
• Patient Education & Validation Validates neurobiological pain; reduces healthcare utilization
• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• FDA-APPROVED • DULOXETINE (Cymbalta) SNRI (30 - 60 mg daily); boosts descending inhibition;
• PHARMACOTHERAPY improves pain, fatigue, and comorbid depression
• MILNACIPRAN (Savella) SNRI (50 mg BID); preferential norepinephrine reuptake
• inhibition; improves pain, fatigue, and "fibro fog"
• PREGABALIN (Lyrica) Alpha-2-delta ligand (150 - 450 mg/day in divided doses);
• reduces glutamate/substance P; restores slow-wave sleep
• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• EVIDENCE-BASED • Cyclobenzaprine (Flexeril) 5 to 10 mg at bedtime; 5-HT2 receptor antagonist;
• OFF-LABEL THERAPY improves sleep architecture and morning stiffness
• Amitriptyline (Elavil) 10 to 25 mg at bedtime; tricyclic antidepressant;
• improves non-restorative sleep; anticholinergic side effects
• Gabapentin (Neurontin) Alternative alpha-2-delta ligand (300 - 1800 mg/day)
• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• STRICTLY CONTRAINDICATED • OPIOID ANALGESICS INEFFECTIVE for centralized nociplastic pain; triggers
• (DO NOT PRESCRIBE) (Oxycodone, Codeine, Tramadol) OPIOID-INDUCED HYPERALGESIA (OIH), dependence, falls
• SYSTEMIC CORTICOSTEROIDS ABSOLUTELY INEFFECTIVE (no tissue inflammation);
• (Prednisone, Methylprednisolone) severe iatrogenic morbidity (osteoporosis, Cushingoid)
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• 1. Non-Pharmacologic Therapy: The First-Line Foundation

Non-pharmacologic modalities provide the highest long-term effect sizes in clinical trials and must be established before or alongside medications:

Graded Low-Impact Aerobic Exercise : The single most effective therapy. Modalities include brisk walking, stationary cycling, swimming, and warm-water pool aquatic therapy. The crucial clinical instruction is "start low and go slow" : patients should begin with just 5 to 10 minutes of gentle exercise 2 to 3 days per week and titrate upward by 10% every 1 to 2 weeks toward a target of 30 to 45 minutes of moderate aerobic activity 3 to 4 days per week. Initiating vigorous exercise abruptly triggers severe post-exertional symptom flares and leads to immediate treatment abandonment.

Cognitive Behavioral Therapy (CBT) : Focuses on identifying and reframing cognitive distortions, decreasing pain catastrophizing, pacing daily physical activities to prevent "boom-and-bust" cycles, and developing active behavioral coping strategies.

Sleep Hygiene : Establishing rigid sleep-wake times, maintaining a dark and cool bedroom environment, eliminating screens 2 hours prior to bed, and eliminating caffeine after noon.

2. FDA-Approved Pharmacotherapies: Dosing & Clinical Selection

Pharmacotherapy should be viewed as an adjunct to facilitate participation in exercise and CBT, rather than a standalone cure. Medications should be selected based on the patient's dominant symptom profile:

Duloxetine (Cymbalta) : Serotonin-Norepinephrine Reuptake Inhibitor (SNRI). Initial dose: 30 mg orally once daily in the morning for 1 week to minimize nausea, then titrate to the target therapeutic dose of 60 mg once daily . Enhances descending serotonergic and noradrenergic inhibitory pain gating. Ideal first-line agent when fibromyalgia co-exists with major depressive disorder, generalized anxiety, or severe chronic fatigue . Common adverse effects include nausea, dry mouth, insomnia, constipation, and mild blood pressure elevations.

Milnacipran (Savella) : SNRI with a distinct pharmacodynamic profile exhibiting greater potency for norepinephrine reuptake inhibition than serotonin (approximately 3:1 ratio). Dose: Titrate over 1 to 2 weeks to 50 mg orally twice daily (100 mg/day). Highly effective for patients in whom fatigue and cognitive dysfunction ("fibro fog") predominate. Adverse effects include nausea, headache, tachycardia, palpitations, hypertension, and hyperhidrosis.

Pregabalin (Lyrica) : Alpha-2-delta ligand. Initial dose: 75 mg orally twice daily (or 50 mg three times daily; 150 mg/day), titrating over 1 to 2 weeks to 150 mg twice daily (300 mg/day) ; maximum dose 450 mg/day. Binds presynaptic voltage-gated P/Q-type calcium channel alpha-2-delta subunits in the spinal cord dorsal horn, reducing calcium influx and inhibiting the exocytosis of glutamate and substance P. Highly preferred when severe non-restorative sleep and anxiety predominate, as pregabalin significantly increases restorative slow-wave sleep. Common adverse effects include dizziness, somnolence, peripheral edema, ataxia, and weight gain. Dose adjustment is mandatory in renal impairment.

3. Strictly Contraindicated Medications in Fibromyalgia

Opioids Are Strictly Contraindicated : Controlled trials consistently show that opioids (including codeine, hydrocodone, oxycodone, morphine, and tramadol) are completely ineffective for centralized nociplastic pain. Furthermore, chronic opioid administration downregulates endogenous mu-opioid receptors, activates spinal microglial toll-like receptor 4 (TLR-4), and induces Opioid-Induced Hyperalgesia (OIH) —a paradoxical, severe amplification of widespread pain sensitivity. Opioids cause physical dependence, addiction, accidental overdose, sedation, cognitive worsening, and severe constipation.

Systemic Corticosteroids Are Strictly Contraindicated : Fibromyalgia is devoid of systemic or synovial tissue inflammation. Corticosteroids (e.g., prednisone, methylprednisolone) have zero clinical efficacy and expose patients to life-threatening complications, including osteoporotic fractures, avascular necrosis, diabetes mellitus, adrenal insufficiency, and severe weight gain.

Differential Diagnosis of Chronic Myopathies

When evaluating patients with chronic musculoskeletal symptoms, primary care clinicians must distinguish true objective muscular weakness from the diffuse pain, stiffness, and subjective fatigue characteristic of fibromyalgia. A patient with fibromyalgia complains that "everything hurts and I feel weak," but demonstrates normal manual muscle testing (5/5 strength throughout). Conversely, patients with true myopathies exhibit objective weakness (e.g., inability to rise from a chair without using hands, difficulty lifting arms above shoulders) and often possess abnormal muscle enzymes. DIFFERENTIAL DIAGNOSIS OF CHRONIC MYOPATHIES

• Disorder Clinical Presentation Creatine Kinase (CK) Distinguishing Diagnostic Features & Biopsy
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Statin-Induced Bilateral symmetric proximal aching, Mild elevation to Symptoms resolve 2-4 weeks post-statin stop;

Myopathy stiffness, or weakness after statin marked (> 10x ULN in ANTI-HMGCR ANTIBODIES in necrotizing autoimmune

• initiation or dose titration true myositis) myopathy (IMNM) that persists after stopping drug
• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Hypothyroid Proximal muscle weakness, cramping, ELEVATED ELEVATED TSH, low free T4; DELAYED RELAXATION
• Myopathy fatigue, and sluggish deep tendon (Typically 5 - 10x OF DEEP TENDON REFLEXES (pseudomyotonia);
• reflexes ULN; up to 50x) myoedema on muscle percussion; resolves w/ levothyroxine
• ─────────────────────────────────────────────────────────────────────────────────────────────────────────

Glucocorticoid-Induced Insidious, PAINLESS symmetric proximal COMPLETELY NORMAL Fast-twitch Type IIb muscle fiber atrophy;

Myopathy weakness (pelvic >> shoulder girdle); (CK normal; ESR/CRP develops with prednisone >= 20 mg/day for > 4-6 wks;

• difficulty rising from low chair normal) resolves with steroid dose reduction & resistance PT
• ─────────────────────────────────────────────────────────────────────────────────────────────────────────

Polymyositis / Subacute symmetric proximal weakness MARKEDLY ELEVATED SKIN SIGNS IN DERMATOMYOSITIS (Heliotrope rash,

Dermatomyositis (neck flexors, deltoids, hip flexors); (10 - 50x ULN; Gottron papules, Shawl sign, mechanic's hands);

• dysphagia in 30-40% of patients elevated aldolase) Anti-Jo-1 antibodies; cancer screening mandatory in DM
• ─────────────────────────────────────────────────────────────────────────────────────────────────────────

Inclusion Body Older adults (> 50y); Male > Female; NORMAL TO MILDLY ASYMMETRIC WEAKNESS OF DEEP FINGER FLEXORS

Myositis (IBM) insidious progression over years; ELEVATED (< 10x ULN; (FDP: cannot grip objects/turn keys) AND QUADRICEPS

• frequent falls (knee buckling) often 300 - 800 U/L) (falls); Biopsy: RIMMED VACUOLES with amyloid/tau
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Clinical Nuances of Major Myopathic Entities

Statin-Associated Muscle Symptoms (SAMS) :

Statin Myalgia : Muscle aching or stiffness without objective weakness and with a normal CK . Management: Temporarily discontinue the statin for 2 to 4 weeks until symptoms resolve; rechallenge at a lower dose, switch to a hydrophilic statin (pravastatin, rosuvastatin), or initiate an alternate-day dosing schedule (e.g., rosuvastatin 5 mg twice weekly) or non-statin lipid-lowering therapy (ezetimibe, PCSK9 inhibitors).

Statin-Induced Immune-Mediated Necrotizing Myopathy (IMNM) : A rare autoimmune disorder triggered by statin exposure. Presents with progressive, severe proximal weakness and markedly elevated CK (typically >10-20x ULN) that continues to worsen even after the statin is stopped . Diagnosis is confirmed by anti-HMG-CoA reductase (anti-HMGCR) autoantibodies and muscle biopsy showing myofiber necrosis with minimal inflammatory infiltrate. Requires aggressive immunosuppression with high-dose corticosteroids, methotrexate, and IVIG.

Hypothyroid Myopathy :

Hypothyroidism commonly presents with proximal muscle weakness, fatigue, muscle stiffness, and cramping. Physical examination reveals delayed relaxation of deep tendon reflexes ("hung-up" reflexes or pseudomyotonia) . Percussion of the muscle belly may elicit myoedema —a transient, localized mounding or swelling of muscle tissue lasting several seconds caused by delayed calcium re-uptake into the sarcoplasmic reticulum.

Laboratory evaluation reveals markedly elevated serum CK (often 5 to 10 times ULN, occasionally up to 50 times ULN) accompanied by an elevated TSH and low free T4. Muscle symptoms and enzyme elevations resolve completely over 2 to 6 months following thyroid hormone replacement with levothyroxine .

Glucocorticoid-Induced Myopathy :

The most common drug-induced toxic myopathy. Caused by high-dose or prolonged systemic corticosteroid therapy (prednisone >=20 mg/day for >4-6 weeks, or fluorinated steroids such as dexamethasone and triamcinolone).

Presents as insidious, painless , symmetric proximal muscle weakness, predominantly involving the pelvic girdle (difficulty rising from a chair or climbing stairs; upper extremities and neck muscles are relatively spared).

Cardinal Diagnostic Feature : Serum Creatine Kinase (CK) is COMPLETELY NORMAL , and ESR/CRP are normal. Pathophysiology involves selective catabolism and atrophy of fast-twitch glycolytic Type IIb muscle fibers. Management consists of tapering the corticosteroid to the lowest possible dose or switching to alternate-day dosing, combined with resistance physical therapy.

Inclusion Body Myositis (IBM) :

The most common acquired myopathy in individuals aged >50 years , with a strong male predominance (2:1).

Characterized by an insidious onset over years and a highly distinctive ASYMMETRIC pattern of weakness involving both proximal and distal muscle groups:

Deep Finger Flexors : Selective weakness and wasting of the flexor digitorum profundus (FDP) and flexor pollicis longus (FPL). Patients cannot make a tight fist, turn door keys, open jars, or carry grocery bags.

Quadriceps Femoris : Severe atrophy of the quadriceps leads to early knee buckling during ambulation and recurrent, traumatic falls.

Pharyngeal Muscles : Severe dysphagia occurs in 40% to 60% of patients.

Laboratory testing reveals a normal or only mildly elevated CK (typically <10x ULN). Muscle biopsy is diagnostic, demonstrating endomysial inflammation, rimmed vacuoles containing basophilic debris, and cytoplasmic/nuclear inclusions of amyloid and hyperphosphorylated tau protein.

Crucially, IBM is refractory to corticosteroids and conventional immunosuppressive medications . Treatment focuses on supportive physical therapy, assistive walking devices, fall prevention, and swallowing evaluations.

Loading diagram... Algorithmic Approach to Generalized Musculoskeletal Pain vs Objective Proximal Muscle Weakness